comparemela.com
Latest Breaking News On - Cmet overexpression - Page 1 : comparemela.com
FDA Grants Fast Track Status to MYTX-011 for NSCLC With cMET Overexpression
The FDA has granted fast track designation to MYTX-011 for use as a potential therapeutic option in patients with non–small cell lung cancer and cMET overexpression.
Massachusetts
United-states
Brian-fiske
International-conference-on-molecular
Mythic-therapeutics
Massachusetts-general-hospital
Molecular-targets
Lung-cancer
News
Metastatic-non-small-cell-lung-cancer
Nsclc
Mytx-011
vimarsana © 2020. All Rights Reserved.